Form 4: CEO Jason Okazaki Receives Equity Grant at Assembly Bio
Statement of Changes in Beneficial Ownership
CEO and President Jason Okazaki acquired 50,750 restricted stock units following shareholder approval of an incentive plan amendment.
Summary
- CEO and President Jason Okazaki was granted 50,750 restricted stock units (RSUs) as part of his annual equity compensation.
- The grant was contingent upon shareholder approval of an amendment to the 2018 Stock Incentive Plan, which was secured on June 4, 2026.
- The RSUs vest in four equal annual installments starting March 29, 2027, through March 29, 2030.
- The reporting person's total beneficial ownership increased to 163,354 shares, including 688 shares acquired via the Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company fundamentals.
Positives
- Alignment of executive compensation with long-term shareholder interests through multi-year vesting schedules.
- Successful shareholder approval of the 2018 Stock Incentive Plan amendment, providing necessary equity capacity for talent retention.
Negatives
- Dilutive impact on existing shareholders due to the issuance of new equity under the incentive plan.
Risks
- Vesting is contingent upon continuous service, creating potential retention risk if the executive departs before 2030.
Future Outlook
The equity grant structure indicates a commitment to long-term retention of the CEO, with vesting scheduled annually through March 2030.
Management Comments
- The grant represents 35% of the reporting person's annual equity compensation.
Industry Context
StockSavvy.ai notes that equity-based compensation remains the standard for biotech leadership to align executive incentives with clinical and commercial milestones.
Comparison to Industry Standards
- The four-year vesting schedule is consistent with standard industry practices for executive equity compensation in the biotechnology sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Incentive Plan Amendment | Shareholders approved an increase in the number of shares authorized for issuance under the 2018 Stock Incentive Plan. | 06/04/2026 | Increases the company's capacity to issue equity-based compensation to employees and directors. |
Stakeholder Impact
- Shareholders experience minor dilution from the issuance of new shares under the incentive plan.
Next Steps
- Vesting of the first tranche of RSUs on March 29, 2027.
Key Dates
| Date | Description |
|---|---|
| 03/29/2026 | Date of RSU grant approval and initial transaction date. |
| 05/14/2026 | Date of ESPP share acquisition. |
| 06/04/2026 | Date of shareholder approval for the Plan Amendment. |
| 03/29/2027 | First vesting date for the RSU grant. |
Keywords
Assembly Biosciences, ASMB, Insider Trading, Executive Compensation, Form 4, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.